drugset / Trial / NCT03332121
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non Hodgkin's lymphoma. It will also explore the PK/PD manner and ORR in this study.
Timeline
- Start
- 2018-03-22
- Primary completion
- 2020-11-30
- Completion
- 2021-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B001 | Monoclonal antibody | 350 mg | Intravenous |
| Subject | B001 | Monoclonal antibody | 700 mg | Intravenous |
| Subject | B001 | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | B001 | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | B001 | Monoclonal antibody | 2000 mg | Intravenous |